CYP2C8
MOLECULAR TARGETcytochrome P450 family 2 subfamily C member 8
CYP2C8 (cytochrome P450 family 2 subfamily C member 8) is targeted by 8 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CYP2C8
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Quercetin | 1.79 | 5 |
| 2 | Phenelzine | 1.10 | 2 |
| 3 | Simvastatin | 0.69 | 1 |
| 4 | Clotrimazole | 0.69 | 1 |
| 5 | Danazol | 0.69 | 1 |
| 6 | Gemfibrozil | 0.69 | 1 |
| 7 | Imatinib Mesylate | 0.69 | 1 |
| 8 | Loratadine | 0.69 | 1 |
About CYP2C8 as a Drug Target
CYP2C8 (cytochrome P450 family 2 subfamily C member 8) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 8 compounds with documented CYP2C8 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CYP2C8 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.